Malaria has a new foe, but it might need some more prep time to start working towards humanity’s (or at least the Bill and Melinda Gates Foundation’s) ultimate goal of malaria eradication. The new drug, Tafenoquine, is approved and ready to start fighting infections, but it has the unfortunate side effect of making red blood cells burst in some patients. Cells dying, you might have guessed, doesn’t lead to great patient outcomes. There is a test that can identify vulnerable patients, but it requires expensive and difficult to use machinery which may not be present in outbreak regions. Never fear though, researchers are already working on creating a more economically and technically feasible testing method that they’re confident will be ready when endemic countries roll out the drug.